![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CEBPA |
Gene summary for CEBPA |
![]() |
Gene information | Species | Human | Gene symbol | CEBPA | Gene ID | 1050 |
Gene name | CCAAT enhancer binding protein alpha | |
Gene Alias | C/EBP-alpha | |
Cytomap | 19q13.11 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P49715 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1050 | CEBPA | LZE4T | Human | Esophagus | ESCC | 1.37e-02 | 5.32e-02 | 0.0811 |
1050 | CEBPA | LZE24T | Human | Esophagus | ESCC | 2.83e-07 | 9.25e-02 | 0.0596 |
1050 | CEBPA | LZE21T | Human | Esophagus | ESCC | 1.94e-03 | 1.47e-01 | 0.0655 |
1050 | CEBPA | P1T-E | Human | Esophagus | ESCC | 3.11e-06 | 5.20e-01 | 0.0875 |
1050 | CEBPA | P2T-E | Human | Esophagus | ESCC | 2.41e-14 | 2.09e-01 | 0.1177 |
1050 | CEBPA | P4T-E | Human | Esophagus | ESCC | 9.29e-07 | 1.48e-01 | 0.1323 |
1050 | CEBPA | P5T-E | Human | Esophagus | ESCC | 4.62e-02 | 3.08e-02 | 0.1327 |
1050 | CEBPA | P8T-E | Human | Esophagus | ESCC | 4.63e-16 | 1.82e-01 | 0.0889 |
1050 | CEBPA | P9T-E | Human | Esophagus | ESCC | 1.92e-13 | 3.61e-01 | 0.1131 |
1050 | CEBPA | P10T-E | Human | Esophagus | ESCC | 2.90e-19 | 3.66e-01 | 0.116 |
1050 | CEBPA | P11T-E | Human | Esophagus | ESCC | 1.82e-09 | 2.16e-01 | 0.1426 |
1050 | CEBPA | P12T-E | Human | Esophagus | ESCC | 1.58e-17 | 3.30e-01 | 0.1122 |
1050 | CEBPA | P15T-E | Human | Esophagus | ESCC | 4.95e-21 | 5.47e-01 | 0.1149 |
1050 | CEBPA | P16T-E | Human | Esophagus | ESCC | 4.76e-04 | 5.12e-02 | 0.1153 |
1050 | CEBPA | P20T-E | Human | Esophagus | ESCC | 6.65e-08 | 1.23e-01 | 0.1124 |
1050 | CEBPA | P22T-E | Human | Esophagus | ESCC | 1.12e-18 | 2.37e-01 | 0.1236 |
1050 | CEBPA | P23T-E | Human | Esophagus | ESCC | 9.10e-14 | 2.34e-01 | 0.108 |
1050 | CEBPA | P26T-E | Human | Esophagus | ESCC | 2.70e-14 | 1.38e-01 | 0.1276 |
1050 | CEBPA | P27T-E | Human | Esophagus | ESCC | 2.04e-02 | 7.49e-02 | 0.1055 |
1050 | CEBPA | P28T-E | Human | Esophagus | ESCC | 2.84e-12 | 2.53e-01 | 0.1149 |
Page: 1 2 3 4 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Stomach | WIM | ![]() |
Stomach | SIM | ![]() |
Liver | NAFLD | ![]() |
Liver | Cirrhotic | ![]() |
Liver | HCC | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0010498111 | Esophagus | ESCC | proteasomal protein catabolic process | 369/8552 | 490/18723 | 1.13e-41 | 1.80e-38 | 369 |
GO:0043161111 | Esophagus | ESCC | proteasome-mediated ubiquitin-dependent protein catabolic process | 312/8552 | 412/18723 | 3.53e-36 | 4.48e-33 | 312 |
GO:0042176111 | Esophagus | ESCC | regulation of protein catabolic process | 280/8552 | 391/18723 | 8.65e-26 | 2.39e-23 | 280 |
GO:0006091110 | Esophagus | ESCC | generation of precursor metabolites and energy | 331/8552 | 490/18723 | 3.86e-23 | 8.45e-21 | 331 |
GO:0009896111 | Esophagus | ESCC | positive regulation of catabolic process | 332/8552 | 492/18723 | 4.36e-23 | 9.22e-21 | 332 |
GO:0031331111 | Esophagus | ESCC | positive regulation of cellular catabolic process | 292/8552 | 427/18723 | 8.67e-22 | 1.53e-19 | 292 |
GO:1903362111 | Esophagus | ESCC | regulation of cellular protein catabolic process | 188/8552 | 255/18723 | 5.12e-20 | 6.62e-18 | 188 |
GO:0045862111 | Esophagus | ESCC | positive regulation of proteolysis | 256/8552 | 372/18723 | 7.88e-20 | 9.43e-18 | 256 |
GO:1903050111 | Esophagus | ESCC | regulation of proteolysis involved in cellular protein catabolic process | 163/8552 | 221/18723 | 1.44e-17 | 1.27e-15 | 163 |
GO:0061136111 | Esophagus | ESCC | regulation of proteasomal protein catabolic process | 142/8552 | 187/18723 | 2.40e-17 | 2.00e-15 | 142 |
GO:0045732111 | Esophagus | ESCC | positive regulation of protein catabolic process | 167/8552 | 231/18723 | 1.47e-16 | 1.14e-14 | 167 |
GO:0032434111 | Esophagus | ESCC | regulation of proteasomal ubiquitin-dependent protein catabolic process | 107/8552 | 134/18723 | 4.06e-16 | 2.93e-14 | 107 |
GO:000170119 | Esophagus | ESCC | in utero embryonic development | 243/8552 | 367/18723 | 1.00e-15 | 6.86e-14 | 243 |
GO:2000058111 | Esophagus | ESCC | regulation of ubiquitin-dependent protein catabolic process | 125/8552 | 164/18723 | 1.17e-15 | 7.76e-14 | 125 |
GO:1903364111 | Esophagus | ESCC | positive regulation of cellular protein catabolic process | 117/8552 | 155/18723 | 3.25e-14 | 1.66e-12 | 117 |
GO:1901800110 | Esophagus | ESCC | positive regulation of proteasomal protein catabolic process | 91/8552 | 114/18723 | 6.74e-14 | 3.34e-12 | 91 |
GO:1903052110 | Esophagus | ESCC | positive regulation of proteolysis involved in cellular protein catabolic process | 101/8552 | 133/18723 | 9.58e-13 | 4.19e-11 | 101 |
GO:0010563111 | Esophagus | ESCC | negative regulation of phosphorus metabolic process | 274/8552 | 442/18723 | 2.32e-12 | 9.41e-11 | 274 |
GO:0045936111 | Esophagus | ESCC | negative regulation of phosphate metabolic process | 273/8552 | 441/18723 | 3.18e-12 | 1.25e-10 | 273 |
GO:0048732111 | Esophagus | ESCC | gland development | 269/8552 | 436/18723 | 7.81e-12 | 2.95e-10 | 269 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04932210 | Esophagus | ESCC | Non-alcoholic fatty liver disease | 122/4205 | 155/8465 | 5.69e-14 | 1.59e-12 | 8.14e-13 | 122 |
hsa052215 | Esophagus | ESCC | Acute myeloid leukemia | 49/4205 | 67/8465 | 7.43e-05 | 3.07e-04 | 1.57e-04 | 49 |
hsa052028 | Esophagus | ESCC | Transcriptional misregulation in cancer | 116/4205 | 193/8465 | 2.08e-03 | 5.95e-03 | 3.05e-03 | 116 |
hsa0493238 | Esophagus | ESCC | Non-alcoholic fatty liver disease | 122/4205 | 155/8465 | 5.69e-14 | 1.59e-12 | 8.14e-13 | 122 |
hsa0522113 | Esophagus | ESCC | Acute myeloid leukemia | 49/4205 | 67/8465 | 7.43e-05 | 3.07e-04 | 1.57e-04 | 49 |
hsa0520213 | Esophagus | ESCC | Transcriptional misregulation in cancer | 116/4205 | 193/8465 | 2.08e-03 | 5.95e-03 | 3.05e-03 | 116 |
hsa0493222 | Liver | Cirrhotic | Non-alcoholic fatty liver disease | 106/2530 | 155/8465 | 2.16e-23 | 2.40e-21 | 1.48e-21 | 106 |
hsa0493232 | Liver | Cirrhotic | Non-alcoholic fatty liver disease | 106/2530 | 155/8465 | 2.16e-23 | 2.40e-21 | 1.48e-21 | 106 |
hsa0493242 | Liver | HCC | Non-alcoholic fatty liver disease | 124/4020 | 155/8465 | 4.54e-17 | 2.54e-15 | 1.41e-15 | 124 |
hsa05221 | Liver | HCC | Acute myeloid leukemia | 41/4020 | 67/8465 | 1.64e-02 | 3.90e-02 | 2.17e-02 | 41 |
hsa0493252 | Liver | HCC | Non-alcoholic fatty liver disease | 124/4020 | 155/8465 | 4.54e-17 | 2.54e-15 | 1.41e-15 | 124 |
hsa052211 | Liver | HCC | Acute myeloid leukemia | 41/4020 | 67/8465 | 1.64e-02 | 3.90e-02 | 2.17e-02 | 41 |
hsa0493228 | Oral cavity | OSCC | Non-alcoholic fatty liver disease | 124/3704 | 155/8465 | 1.22e-20 | 1.37e-18 | 6.96e-19 | 124 |
hsa052214 | Oral cavity | OSCC | Acute myeloid leukemia | 42/3704 | 67/8465 | 1.34e-03 | 3.75e-03 | 1.91e-03 | 42 |
hsa04932112 | Oral cavity | OSCC | Non-alcoholic fatty liver disease | 124/3704 | 155/8465 | 1.22e-20 | 1.37e-18 | 6.96e-19 | 124 |
hsa0522112 | Oral cavity | OSCC | Acute myeloid leukemia | 42/3704 | 67/8465 | 1.34e-03 | 3.75e-03 | 1.91e-03 | 42 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 2 3 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CEBPA | SNV | Missense_Mutation | rs780335632 | c.803N>T | p.Gly268Val | p.G268V | P49715 | protein_coding | tolerated(0.09) | benign(0.001) | TCGA-C5-A3HL-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
CEBPA | SNV | Missense_Mutation | c.840N>C | p.Lys280Asn | p.K280N | P49715 | protein_coding | deleterious(0) | probably_damaging(0.92) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD | |
CEBPA | SNV | Missense_Mutation | c.1015C>T | p.Arg339Trp | p.R339W | P49715 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
CEBPA | SNV | Missense_Mutation | c.947A>C | p.Glu316Ala | p.E316A | P49715 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
CEBPA | SNV | Missense_Mutation | novel | c.955A>G | p.Ser319Gly | p.S319G | P49715 | protein_coding | tolerated(0.05) | benign(0.171) | TCGA-AA-A01P-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
CEBPA | SNV | Missense_Mutation | c.1073N>T | p.Ala358Val | p.A358V | P49715 | protein_coding | deleterious(0.01) | possibly_damaging(0.788) | TCGA-EC-A1QX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamide | PD | |
CEBPA | SNV | Missense_Mutation | c.866N>A | p.Arg289His | p.R289H | P49715 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-VQ-A8PP-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | fluorouracil | PD | |
CEBPA | SNV | Missense_Mutation | novel | c.869N>T | p.Glu290Val | p.E290V | P49715 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-VQ-A91K-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | fluorouracil | CR |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1050 | CEBPA | TRANSCRIPTION FACTOR COMPLEX, TRANSCRIPTION FACTOR, CLINICALLY ACTIONABLE | OICR-9429 | 26167872 | ||
1050 | CEBPA | TRANSCRIPTION FACTOR COMPLEX, TRANSCRIPTION FACTOR, CLINICALLY ACTIONABLE | N/A | 20038735,26601784,19171880,22814295,25241285,23521373 |
Page: 1 |